Diagnostics & Research · CAMBRIDGE, MA, United States
$12.61
-0.47% (-$0.06)2026-05-26
Revenue$23.0M
Net Income-$95.8M
EPS$-3.81
Market Cap$1.5B
Price Performance
Historical data including institutional events
Loading price data...
Company Profile
J
John Leonard
CEO & Executive Director
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.